Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIGHTZYME is an oral enzymatic syrup marketed by Varmed Pharma, an Indian PCD pharma franchise company. It is a combination formulation containing fungal diastase and pepsin, designed to assist in the digestion of carbohydrates and proteins. Fungal diastase is an amylolytic enzyme derived from Aspergillus oryzae that hydrolyzes starch into simpler sugars like maltose, while pepsin is a proteolytic enzyme that breaks down proteins into smaller peptides. The product is primarily used as a digestive supplement to manage symptoms of dyspepsia, flatulence, and other digestive disorders where endogenous enzyme production may be insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RIGHTZYME.